Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
The purpose of this study is to elucidate whether the individualized medicine based on NAT2
 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug
 therapy for the pulmonary tuberculosis with isoniazid.
Inclusion Criteria:

 -  Newly diagnosed pulmonary tuberculosis patients

 -  Informed consent including pharmacogenomic analysis

 Exclusion Criteria:

 -  Abnormal liver and kidney function test before treatment

 -  Long-term use of steroids and/or immunodepressants

 -  Inadequate clinical conditions